Enhancement of empathy, creative thinking, and subjective well-being outlasts the intoxication.
Increased mindfulness and decreased anxiety, depression, and stress were seen right away, becoming more significant four weeks after dosing.
The context of the psychedelic experience plays a critical role in determining positive outcomes for patients.
The answer is yes and no. It's a matter of perspective.
Improvements in depression and anxiety are associated with greater intensity of mystical experiences and higher ratings of the spiritual significance and personal meaning.
Bruce Tobin is asking Health Canada to approve psilocybin to treat anxiety and depression in end-of-life patients.
FDA approval for psilocybin-assisted therapy for depression appears to be on the horizon.
Researchers push to move psilocybin from Schedule I to Schedule IV if Phase III clinical trials are successful.
The FDA will work to expedite the development and review of the drug so it can get to patients as soon as possible.
Researchers measured the effects of psilocybin by comparing brain scans.